Aquestive Therapeutics, Inc. AQST Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Sep'17	Jun'17
Revenues
48,731	52,609	53,014	53,863	56,662	67,430	0	0	0	-	-
Revenues
-	-	-	-	-	-	-	-	-	0	0
Costs and expenses:
The aggregate costs incurred in the production of goods and supply for sale.
20,514	20,361	18,356	19,305	18,858	20,988	0	0	0	0	0
Research and development
20,625	20,574	23,200	22,671	22,514	23,112	0	0	0	0	0
Selling, general and administrative
61,047	64,342	66,554	65,186	82,608	72,269	0	0	0	0	0
Total costs and expenses
102,186	105,277	108,110	107,162	123,980	116,369	0	0	0	0	0
Loss from operations
-53,455	-52,668	-55,091	-53,294	-67,313	-48,934	0	0	0	0	0
Other income/(expenses):
Interest expense
10,163	9,318	8,439	7,720	7,710	7,711	0	0	0	0	0
Interest income
464	636	877	955	802	552	0	0	0	0	-
Loss on the extinguishment of debt
-	-	0	-	-	-	0	-	-	-	-
Change in fair value of warrant
-	-	0	4,116	-	5,278	0	0	0	0	0
Other, net
-	-	-	-	-	-	-	-	-	0	0
Net loss before income taxes
-68,050	-66,246	-67,554	-64,180	-80,201	-61,376	0	0	0	0	0
Income taxes
0	0	0	0	0	0	0	0	0	0	0
Net loss
-68,050	-66,246	-67,554	-64,180	-80,201	-61,376	0	0	0	0	0
Dividends on redeemable preferred interests
-	-	-	-	-	-	-	-	-	0	0
Net loss attributable to common shares/ members' interests
-	-	-	-	-	-	-	-	-	0	0
Comprehensive loss
-68,050	-66,246	-67,554	-64,180	-80,201	-61,376	0	0	0	0	0
Net loss per share - basic and diluted (in dollars per share)
-0.49	-0.46	-0.74	-0.82	-0.59	-0.69	-0.64	-1.90	0.27	-	-
Weighted-average number of common shares outstanding - basic and diluted (in shares)
33,569	26,448	25,031	24,980	24,963	24,989	23,646	19,188	15,077	-	-